These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1082 related items for PubMed ID: 12107214

  • 21. Measurement of basal growth hormone (GH) is a useful test of disease activity in treated acromegalic patients.
    Jayasena CN, Wujanto C, Donaldson M, Todd JF, Meeran K.
    Clin Endocrinol (Oxf); 2008 Jan; 68(1):36-41. PubMed ID: 18088288
    [Abstract] [Full Text] [Related]

  • 22. DISCORDANCE BETWEEN GH AND IGF-1 LEVELS IN TURKISH ACROMEGALIC PATIENTS.
    Cerit ET, Ağbaht K, Demir Ö, Şahin M, Gedik VT, Özcan C, Çorapçıoğlu D.
    Endocr Pract; 2016 Dec; 22(12):1422-1428. PubMed ID: 27631850
    [Abstract] [Full Text] [Related]

  • 23. Biochemical evidence supporting the Cortina criteria.
    von Werder K.
    J Endocrinol Invest; 2005 Dec; 28(11 Suppl International):81-3. PubMed ID: 16625853
    [Abstract] [Full Text] [Related]

  • 24. GH and mortality in acromegaly.
    Sheppard MC.
    J Endocrinol Invest; 2005 Dec; 28(11 Suppl International):75-7. PubMed ID: 16625851
    [Abstract] [Full Text] [Related]

  • 25. Dynamic tests and basal values for defining active acromegaly.
    Tzanela M.
    Neuroendocrinology; 2006 Dec; 83(3-4):200-4. PubMed ID: 17047383
    [Abstract] [Full Text] [Related]

  • 26. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS, Neskovic AN, Petakov MS, Popovic V, Macut D, Vukojevic P, Joksimovic MM.
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [Abstract] [Full Text] [Related]

  • 27. GH response to oral glucose tolerance test: a comparison between patients with acromegaly and other pituitary disorders.
    Verrua E, Filopanti M, Ronchi CL, Olgiati L, Ferrante E, Giavoli C, Sala E, Mantovani G, Arosio M, Beck-Peccoz P, Lania AG, Spada A.
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E83-8. PubMed ID: 20962023
    [Abstract] [Full Text] [Related]

  • 28. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
    Espinosa-de-los-Monteros AL, Mercado M, Sosa E, Lizama O, Guinto G, Lopez-Felix B, Garcia O, Hernández I, Ovalle A, Mendoza V.
    J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
    [Abstract] [Full Text] [Related]

  • 29. Serum IGF-I and IGFBP-3 levels for the assessment of disease activity of acromegaly.
    Chen HS, Lin HD.
    J Endocrinol Invest; 1999 Feb; 22(2):98-103. PubMed ID: 10195375
    [Abstract] [Full Text] [Related]

  • 30. Diagnostic value of serum IGF-I and IGFBP-3 in growth hormone disorders in adults.
    Kim HJ, Kwon SH, Kim SW, Park DJ, Shin CS, Park KS, Kim SY, Cho BY, Lee HK.
    Horm Res; 2001 Feb; 56(3-4):117-23. PubMed ID: 11847474
    [Abstract] [Full Text] [Related]

  • 31. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
    Kohler S, Tschopp O, Sze L, Neidert M, Bernays RL, Spanaus KS, Wiesli P, Schmid C.
    Gen Comp Endocrinol; 2013 Jul 01; 188():282-7. PubMed ID: 23648743
    [Abstract] [Full Text] [Related]

  • 32. The role of IGF binding protein-3 as a parameter of activity in acromegalic patients.
    Halperin I, Casamitjana R, Flores L, Fernandez-Balsells M, Vilardell E.
    Eur J Endocrinol; 1999 Aug 01; 141(2):145-8. PubMed ID: 10427158
    [Abstract] [Full Text] [Related]

  • 33. Current concepts in the biochemical assessment of the patient with acromegaly.
    Freda PU.
    Growth Horm IGF Res; 2003 Aug 01; 13(4):171-84. PubMed ID: 12914750
    [Abstract] [Full Text] [Related]

  • 34. Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery.
    Damjanović SS, Petakov MS, Raicević S, Micić D, Marinković J, Dieguez C, Casanueva FF, Popović V.
    J Clin Endocrinol Metab; 2000 Jan 01; 85(1):147-54. PubMed ID: 10634378
    [Abstract] [Full Text] [Related]

  • 35. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up.
    Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL.
    J Clin Endocrinol Metab; 2002 Aug 01; 87(8):3537-42. PubMed ID: 12161471
    [Abstract] [Full Text] [Related]

  • 36. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
    Carmichael JD, Bonert VS, Mirocha JM, Melmed S.
    J Clin Endocrinol Metab; 2009 Feb 01; 94(2):523-7. PubMed ID: 19033371
    [Abstract] [Full Text] [Related]

  • 37. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly.
    Puder JJ, Nilavar S, Post KD, Freda PU.
    J Clin Endocrinol Metab; 2005 Apr 01; 90(4):1972-8. PubMed ID: 15634715
    [Abstract] [Full Text] [Related]

  • 38. Are there alternative tests for diagnosis of acromegaly?
    Popovic V.
    J Endocrinol Invest; 2005 Apr 01; 28(11 Suppl International):73-4. PubMed ID: 16625850
    [Abstract] [Full Text] [Related]

  • 39. Adequacy of current postglucose GH nadir limit (< 1 microg/l) to define long-lasting remission of acromegalic disease.
    Ronchi CL, Arosio M, Rizzo E, Lania AG, Beck-Peccoz P, Spada A.
    Clin Endocrinol (Oxf); 2007 Apr 01; 66(4):538-42. PubMed ID: 17371472
    [Abstract] [Full Text] [Related]

  • 40. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA.
    Clin Endocrinol (Oxf); 2005 Mar 01; 62(3):282-8. PubMed ID: 15730408
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 55.